For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.
Registry Study for Patients with Ulcerative Colitis or Crohn’s Disease
This study is looking at patients who have been diagnosed with ulcerative colitis (UC) or Crohn’s disease (CD) and will be either starting vedolizumab (Entyvio®) or will be starting on another biologic medication for their disease. The purpose of this study is to obtain long-term safety information on the disease and medications that the patient received or are receiving for their inflammatory bowel disease. A description of this clinical trial will be available at www.ClinicalTrials.gov, as required by U.S. law.
In order to participate you must meet the following criteria:
- Have been diagnosed with ulcerative colitis or Crohn’s disease.
- Are starting vedolizumab (Entyvio) or another biologic medication for their disease for the first time.
- Are 18 years of age, or older.
This is a partial list of elgibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.